Year |
Citation |
Score |
2023 |
Tang R, Shuldiner EG, Kelly M, Murray CW, Hebert JD, Andrejka L, Tsai MK, Hughes NW, Parker MI, Cai H, Li YC, Wahl GM, Dunbrack RL, Jackson PK, Petrov DA, et al. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth. Nature Cell Biology. PMID 36635501 DOI: 10.1038/s41556-022-01049-w |
0.374 |
|
2012 |
Hughes N, Mehta S, Winchester L, Han C, Buffa F, Adams R, Harris A. Abstract P4-01-01: Integrating dynamic magnetic resonance imaging and gene expression profiling reveals novel therapeutic targets in locally advanced breast cancer. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-01-01 |
0.408 |
|
2012 |
Mehta S, Hughes N, Adams R, Li S, Han C, Kaur K, Taylor N, Padhani A, Makris A, Buffa F, Harris A. Abstract P1-06-01: Upregulation of metabolism as a potential resistance mechanism to bevacizumab in primary breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P1-06-01 |
0.399 |
|
2011 |
Mehta S, Hughes NP, Buffa FM, Li SP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris AL. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. Journal of the National Cancer Institute. Monographs. 2011: 71-4. PMID 22043045 DOI: 10.1093/jncimonographs/lgr027 |
0.365 |
|
2011 |
Tseng JR, Stuart D, Aardalen K, Kaplan A, Aziz N, Hughes NP, Gambhir SS. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. Neoplasia (New York, N.Y.). 13: 266-75. PMID 21390189 DOI: 10.1593/Neo.101466 |
0.392 |
|
2010 |
Mehta S, Buffa F, Li S, Hughes N, Adams R, Adwani A, Taylor N, Levitt N, Padhani A, Makris A, Harris A. Abstract P2-09-28: Integrated Gene Expression and MRI Analysis To Assess Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-09-28 |
0.373 |
|
2010 |
Hughes N, Mehta S, Li S, Taylor J, Adwani A, Buffa F, Levitt N, Makris A, Adams R, Harris A, Padhani A. Abstract P2-02-07: Predicting Response to Bevacizumab Therapy in Primary Breast Cancer Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-02-07 |
0.356 |
|
Show low-probability matches. |